Biocon Biologics has received an emergency use authorisation (EUA) for its monoclonal antibody Itoliuzumab from the Drug Controller General of India (DCGI) to treat cytokine storms – one of the leading causes of death among patients with severe covid-19.
As per the DCGI, the novel drug can be used only in a hospital set-up, and requires informed consent of patients and a risk management plan.
Itolizumab was launched in 2013 under brand name Alzumab to treat moderate to severe chronic plaque psoriasis. It has been now repurposed for prevention and treatment of covid-19 complications.
Leave a Reply